Zobraziť v EDS

Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions

Uložené v:
Podrobná bibliografia
Názov: Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Autori: Audrey-Anne Lamoureux, Michael J. Fisher, Lauriane Lemelle, Elke Pfaff, Pouneh Amir-Yazdani, Christof Kramm, Bram De Wilde, Bernarda Kazanowska, Caroline Hutter, Stefan M. Pfister, Dominik Sturm, David T.W. Jones, Daniel Orbach, Gaëlle Pierron, Scott Raskin, Alexander Drilon, Eli L. Diamond, Guilherme Harada, Michal Zapotocky, Josef Zamecnik, Lenka Krskova, Benjamin Ellezam, Alexander G. Weil, Dominic Venne, Marc Barritault, Pierre Leblond, Hallie Coltin, Rawan Hammad, Uri Tabori, Cynthia Hawkins, Jordan R. Hansford, Deborah Meyran, Craig Erker, Kathryn McFadden, Mariko Sato, Nicholas G. Gottardo, Hetal Dholaria, Dorte Schou Nørøxe, Hiroaki Goto, David S. Ziegler, Frank Y. Lin, Donald Williams Parsons, Holly Lindsay, Tai-Tong Wong, Yen-Lin Liu, Kuo-Sheng Wu, Andrea T. Franson, Eugene Hwang, Ana Aguilar-Bonilla, Sylvia Cheng, Chantel Cacciotti, Maura Massimino, Elisabetta Schiavello, Paul Wood, Lindsey M. Hoffman, Andréa Cappellano, Alvaro Lassaletta, An Van Damme, Anna Llort, Nicolas U. Gerber, Mariella Spalato Ceruso, Anne E. Bendel, Maggie Skrypek, Dima Hamideh, Naureen Mushtaq, Andrew Walter, Nada Jabado, Aysha Alsahlawi, Jean-Pierre Farmer, Christina Coleman, Sabine Mueller, Claire Mazewski, Dolly Aguilera, Nathan J. Robison, Katrina O’Halloran, Samuel Abbou, Pablo Berlanga, Birgit Geoerger, Ingrid Øra, Christopher L. Moertel, Evangelia D. Razis, Anastasia Vernadou, François Ducray, Charlotte Bronnimann, Romuald Seizeur, Matthew Clarke, Adam C. Resnick, Mélanie Alves, Chris Jones, François Doz, Theodore W. Laetsch, Sébastien Perreault
Prispievatelia: Institut Català de la Salut, [Lamoureux AA, Amir-Yazdani P] Department of Neurosciences, University of Montreal, CHU Sainte-Justine, Montreal, Quebec, Canada. [Fisher MJ] Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania. [Lemelle L] SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris, France. [Pfaff E] Division of Pediatric Glioma Research, Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany. National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany. [Kramm C] Division of Pediatric Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany. [Llort A] Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Lamoureux, Audrey-Anne, Fisher, Michael J., Lemelle, Lauriane, Pfaff, Elke, Amir-Yazdani, Pouneh, Kramm, Christof, De Wilde, Bram, Kazanowska, Bernarda, Hutter, Caroline, Pfister, Stefan M., Perreault, Sébastien
Zdroj: Clin Cancer Res
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
CLINICAL CANCER RESEARCH
Informácie o vydavateľovi: American Association for Cancer Research (AACR), 2024.
Rok vydania: 2024
Predmety: Histology, DISEASES::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms, Pediatric patients, Other subheadings::Other subheadings::/therapy, Sistema nerviós central - Càncer - Tractament, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms, Neuroepithelial::Glioma, Trauma, Precision Medicine and Imaging, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::glioma, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptor Protein-Tyrosine Kinases, Proteïnes quinases - Receptors, Medicine and Health Sciences, PHENOMENA AND PROCESSES::Genetic Phenomena::Recombination, Genetic::Gene Fusion, Nervous system tumors, HGG, Recombinació genètica, Tumors, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema nervioso::neoplasias del sistema nervioso central, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, NAMED GROUPS::Persons::Age Groups::Child::Child, Preschool, FENÓMENOS Y PROCESOS::fenómenos genéticos::recombinación genética::fusión génica, Gliomes - Tractament, Otros calificadores::Otros calificadores::/terapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Neurology, Oncology, Avaluació de resultats (Assistència sanitària), Infants, DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño::niño preescolar, RESPONSE ASSESSMENT, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores proteína-tirosina cinasas
Popis: Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults (P < 0.0001). Patients with LGG also had a better outcome when compared with HGG (P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.
Druh dokumentu: Article
Other literature type
Popis súboru: application/pdf
Jazyk: English
ISSN: 1557-3265
1078-0432
DOI: 10.1158/1078-0432.ccr-24-0581
Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39625867
http://hdl.handle.net/11351/12822
https://aacrjournals.org/clincancerres/article/31/3/561/751212/Clinical-Characteristics-and-Outcomes-of-Central
https://doi.org/10.1158/1078-0432.ccr-24-0581
https://resolver.sub.uni-goettingen.de/purl?gro-2/147235
https://biblio.ugent.be/publication/01JMAGPEXENXKAGM1NDM91GQ2Y
http://hdl.handle.net/1854/LU-01JMAGPEXENXKAGM1NDM91GQ2Y
http://doi.org/10.1158/1078-0432.ccr-24-0581
https://biblio.ugent.be/publication/01JMAGPEXENXKAGM1NDM91GQ2Y/file/01JMAGPQ880HTJXZ0E0WH547CS
Rights: CC BY NC ND
URL: http://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
Prístupové číslo: edsair.doi.dedup.....5f286b886b9f703ea5aa1281e0599e8f
Databáza: OpenAIRE
Popis
Abstrakt:Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults (P < 0.0001). Patients with LGG also had a better outcome when compared with HGG (P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.
ISSN:15573265
10780432
DOI:10.1158/1078-0432.ccr-24-0581